[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553344":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":30,"studyPopulation":30,"armGroups":37,"interventions":44,"overallOfficials":30,"centralContacts":49,"locations":55,"responsibleParty":196,"collaborators":30,"id":198,"slug":30,"hasResults":199,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":30,"eligibilityCriteria":203,"healthyVolunteers":199,"sex":204,"minAge":205,"maxAge":30,"enrollmentInfo":206,"targetDuration":30,"studyType":209,"phases":210,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":58,"whyStopped":30,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":207},{"fullName":5,"class":6},"Amryt Pharma","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":30},[9,13],{"measure":10,"description":11,"timeFrame":12},"Number of patients with decrease of at least 0.5% in glycated haemoglobin (HbA1c) at Month 12 compared to Baseline or HbA1c \u003C6.5 % at Month 12, in patients with baseline HbA1c ≥6.5%.","To evaluate the efficacy (HbA1c) of metreleptin treatment in patients with PL","12 months",{"measure":14,"description":15,"timeFrame":12},"Number of patients with decrease of at least 30% in triglycerides (TG) at Month 12 compared to Baseline, in patients with baseline TG levels ≥500 mg\u002FdL (5.65 mmol\u002FL)","To evaluate the efficacy (TG) of metreleptin treatment in patients with PL",[17,21,23,27],{"measure":18,"description":19,"timeFrame":20},"Number of patients with decrease of at least 0.5% in HbA1c at Month 24 compared to Baseline or HbA1c \u003C6.5 % at Month 24, in patients with baseline HbA1c ≥6.5%.","To evaluate the long-term efficacy of metreleptin treatment in patients with PL","24 months",{"measure":22,"description":19,"timeFrame":20},"Number of patients with decrease of at least 30% in TG levels at Month 24 compared to Baseline, in patients with baseline TG levels ≥500 mg\u002FdL (5.65 mmol\u002FL).",{"measure":24,"description":25,"timeFrame":26},"Change from baseline in liver volume at Month 12 and Month 24","To assess changes in liver volume.","12 months and 24 months",{"measure":28,"description":29,"timeFrame":20},"Incidence of, Treatment emergent adverse events (TEAEs), Deaths and other serious adverse events (SAEs), Treatment related adverse events (AEs), AEs of special interest (AESIs) and AEs leading to study drug discontinuation","To evaluate the safety of metreleptin treatment in patients with PL",null,{"allocation":32,"interventionModel":33,"interventionModelDescription":30,"primaryPurpose":34,"observationalModel":30,"timePerspective":30,"maskingInfo":35},"NA","SINGLE_GROUP","TREATMENT",{"masking":36,"maskingDescription":30,"whoMasked":30},"NONE",[38],{"label":39,"type":40,"description":41,"interventionNames":42},"Metreleptin","EXPERIMENTAL","Metreleptin \\[Recombinant-methionyl human Leptin; r-metHuLeptin\\] for daily injection is a sterile, white, solid lyophilised cake",[43],"Drug: Metreleptin",[45],{"type":46,"name":39,"description":47,"armGroupLabels":48,"otherNames":30},"DRUG","Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency",[39],[50],{"name":51,"role":52,"phone":53,"phoneExt":30,"email":54},"Janet Boylan","CONTACT","+3905212791","clinicaltrials_info@chiesi.com",[56,71,82,90,101,114,126,139,150,161,172,183],{"facility":57,"status":58,"city":59,"state":30,"zip":30,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez","RECRUITING","Lille","France","FR",{"type":63,"coordinates":64},"Point",[65,66],3.05512,50.63391,{"lat":66,"lon":65},[69],{"name":70,"role":52,"phone":30,"phoneExt":30,"email":30},"Marie-Christine Vantyghem",{"facility":72,"status":58,"city":73,"state":30,"zip":30,"country":60,"countryCode":61,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Hopital Pitie-Salpetriere","Paris",{"type":63,"coordinates":75},[76,77],2.3488,48.85341,{"lat":77,"lon":76},[80],{"name":81,"role":52,"phone":30,"phoneExt":30,"email":30},"Fabrizio Andreelli",{"facility":83,"status":58,"city":73,"state":30,"zip":30,"country":60,"countryCode":61,"cosmosGeoPoint":84,"geoPoint":86,"contacts":87},"Hôpital Saint-Antoine",{"type":63,"coordinates":85},[76,77],{"lat":77,"lon":76},[88],{"name":89,"role":52,"phone":30,"phoneExt":30,"email":30},"Corinne Vigouroux",{"facility":91,"status":58,"city":92,"state":30,"zip":30,"country":60,"countryCode":61,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Centre Hospitalier Lyon-Sud","Pierre-Bénite",{"type":63,"coordinates":94},[95,96],4.82424,45.70359,{"lat":96,"lon":95},[99],{"name":100,"role":52,"phone":30,"phoneExt":30,"email":30},"Emmanuel Disse",{"facility":102,"status":58,"city":103,"state":30,"zip":30,"country":104,"countryCode":105,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Charite-Universitaetsmedizin Berlin - Campus Charite Mitte (CCM)","Berlin","Germany","DE",{"type":63,"coordinates":107},[108,109],13.41053,52.52437,{"lat":109,"lon":108},[112],{"name":113,"role":52,"phone":30,"phoneExt":30,"email":30},"Thomas Bobbert",{"facility":115,"status":116,"city":117,"state":30,"zip":30,"country":104,"countryCode":105,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Universitaetsklinikum Ulm - Klinik fuer Kinder- und Jugendmedizin","NOT_YET_RECRUITING","Ulm",{"type":63,"coordinates":119},[120,121],9.99155,48.39841,{"lat":121,"lon":120},[124],{"name":125,"role":52,"phone":30,"phoneExt":30,"email":30},"Martin Wabitsch",{"facility":127,"status":58,"city":128,"state":30,"zip":30,"country":129,"countryCode":130,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi","Bologna","Italy","IT",{"type":63,"coordinates":132},[133,134],11.33875,44.49381,{"lat":134,"lon":133},[137],{"name":138,"role":52,"phone":30,"phoneExt":30,"email":30},"Alessandra Gambineri",{"facility":140,"status":116,"city":141,"state":30,"zip":30,"country":129,"countryCode":130,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"Universitá degli Studi \"Magna Graecia\" di Catanzaro","Catanzaro",{"type":63,"coordinates":143},[144,145],16.60086,38.88247,{"lat":145,"lon":144},[148],{"name":149,"role":52,"phone":30,"phoneExt":30,"email":30},"Antonio Aversa",{"facility":151,"status":58,"city":152,"state":30,"zip":30,"country":129,"countryCode":130,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"Azienda Ospedaliero Universitaria Maggiore della Carità di Novara","Novara",{"type":63,"coordinates":154},[155,156],8.62118,45.44694,{"lat":156,"lon":155},[159],{"name":160,"role":52,"phone":30,"phoneExt":30,"email":30},"Flavia Prodam",{"facility":162,"status":58,"city":163,"state":30,"zip":30,"country":129,"countryCode":130,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"Azienda Ospedaliero Universitaria Pisana - Stabilimento di Cisanello","Pisa",{"type":63,"coordinates":165},[166,167],10.4036,43.70853,{"lat":167,"lon":166},[170],{"name":171,"role":52,"phone":30,"phoneExt":30,"email":30},"Giovanni Ceccarini",{"facility":173,"status":58,"city":174,"state":30,"zip":30,"country":129,"countryCode":130,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"A.S.U Integrata di Udine - Presidio Ospedaliero Santa Maria della Misericordia","Udine",{"type":63,"coordinates":176},[177,178],13.23715,46.0693,{"lat":178,"lon":177},[181],{"name":182,"role":52,"phone":30,"phoneExt":30,"email":30},"Annalisa Sechi",{"facility":184,"status":116,"city":185,"state":30,"zip":30,"country":186,"countryCode":187,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital","Cambridge","United Kingdom","UK",{"type":63,"coordinates":189},[190,191],0.11667,52.2,{"lat":191,"lon":190},[194],{"name":195,"role":52,"phone":30,"phoneExt":30,"email":30},"Anna Stears",{"type":197,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100553344",false,"NCT06484868","Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy","A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients With Partial Lipodystrophy","Inclusion Criteria:\n\n* Confirmed diagnosis of familial or acquired partial lipodystrophy\n\nExclusion Criteria:\n\n* Treatment with any Investigational Medicinal Product (IMP) within 6 months or 5 times the terminal half-life of the corresponding IMP, whichever is longer, before the screening visit.\n\nOther protocol defined inclusion\u002Fexclusion criteria apply","ALL","12 Years",{"count":207,"type":208},12,"ESTIMATED","INTERVENTIONAL",[211],"PHASE4","This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy",[214],"Partial Lipodystrophy",[39],"2025-07-02",{"date":218,"type":219},"2025-07-03","ACTUAL",{"date":221,"type":219},"2024-02-08",{"date":223,"type":208},"2028-02",{"name":5,"class":6}]